On December 21, 2023, 4B Technology announced that its independently developed First-in-Class monoclonal antibody 4B03-04 has received approval from Alfred Clinical Research Ethics Committee to conduct clinical trial in Australia. 4B03-04 was developed for the treatment of chronic pain. 

The First-in-Human clinical trial of 4B03-04 in Australia is a randomized, double-blind, placebo-controlled study to assess the safety, tolerability and pharmacokinetics of single- and multiple-escalating-dose of 4B03-04 in the healthy subjects.

About 4B03-04

4B03-04 is an innovative FIC drug developed by 4B Technologies who holds all the global rights. It targets the clinically validated NGF-TrkA pathway through a unique mechanism of action to modulate TrkA receptor. Therefore, we believe that 4B03-04 has the potential to become a groundbreaking product for chronic pain management. 

Unlike other marketed drugs like NSAIDs and Opioids, in pre-clinical studies, 4B03-04 showed significant pain-killing effect with outstanding safety profile, especially avoided gastrointestinal side effects or drug dependence. Furthermore, due to its unique mechanism of action, 4B03-04 sidesteps adverse reactions caused by complete NGF function blockage by NGF antibodies. With its potential to pioneer a new approach in chronic pain treatment, 4B03-04 stands poised to revolutionize this therapeutic landscape.